BioPharma Dive October 2, 2024
Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.
Roche is in the midst of a revamp. As it cuts some R&D areas to streamline its pipeline, the Swiss drugmaker is betting on sales growth from its portfolio and a new stream of acquisitions to offset headwinds.
By 2028, Roche anticipates sales from a handful of aging biologic blockbusters will be 6.8 billion Swiss francs, or roughly $8 billion, less than what the Swiss pharmaceutical company recorded last year, according to an investor presentation.
However, Roche thinks it can more than compensate for that sales shortfall. According to CEO Thomas Shinecker, the company can cover the anticipated sales...
Today's Sponsors
Today's Sponsor